Fig. 6: Venetoclax was confirmed to be a promising treatment choice for MCL Patient 18.
A In vitro cell viability assay of the designed drug panel on MCL18 primary patient cells. Each bar is the maximum inhibition rate for each agent. B Cell viability assay and apoptosis assay after 24 h treatment of BCL-2 inhibitor venetoclax, MCL-1 inhibitors S63845 and AZD5991 on MCL18-PDX isolated tumor cells ex vivo. C MCL18-PDX mice were treated as indicated: vehicle (n = 5) and venetoclax (50 mg/kg, oral, daily; n = 5). Tumor size was measured every ten days during the treatment. Tumor volume = length x width2/2. Mice were euthanized when one dimension of tumor reached 15 mm. Kaplan-Meier survival curve of PDX tumor–bearing mice from treatment start time in the treatment groups. Blood β2M tested from mouse plasma was plotted to monitor the tumor growth. D Tumor cells were isolated at the endpoint from each mouse. Cell viability was tested using the Trypan Blue dye exclusion method. Results were considered statistically significant at p < 0.05 (*); p < 0.01 (**); p < 0.001 (***), and p < 0.0001 (****).
